MolecuLight^® improves management of
Diabetic Wounds

The presence or absence of red or cyan on bacterial fluorescence images accurately predicted the success or failure of DFU healing after acellular matrix product placement.

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

In a groundbreaking RCT, MolecuLight^® imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%), and the presence or absence of bacterial fluorescence reliably predicted the degree of wound closure.

This compelling data highlights how point-of-care bacterial fluorescence imaging can revolutionize the management of diabetic foot ulcers, leading to superior patient outcomes.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device,​ and fluorescence imaging before and after standard debridement revealed persistence​ of bacterial fluorescence in 100% of DFUs.